NICE approves Botox for migraine prophylaxis

Patients with chronic migraine can now be prescribed botulinum toxin type A (Botox) on the NHS, following a recommendation from NICE.

Botox is also licensed for the reduction of glabellar lines, hyperhidrosis and certain types of muscle spasm and spasticity | SCIENCE PHOTO LIBRARY
Botox is also licensed for the reduction of glabellar lines, hyperhidrosis and certain types of muscle spasm and spasticity | SCIENCE PHOTO LIBRARY
The product can be used in adults with chronic migraine, defined as headaches on at least 15 days per month of which at least 8 days are with migraine. Patients must have not responded to at least three prior pharmacological prophylaxis therapies and must be managed appropriately for medication overuse.

Treatment should be stopped if the response is inadequate after two treatment cycles, that is, if there is a less than 30% reduction in headache days per month, or if the patient’s condition has changed to episodic migraine (fewer than 15 headache days per month) for 3 consecutive months.

Botox is the only botulinum toxin product that is licensed for migraine prophylaxis.

Further details
NICE guidance on botulinum toxin for chronic migraine

Further information
View Botox drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more